Orlando, FL-A study by researchers from Memorial Sloan-Kettering Cancer Center in New York has given added strength to the recommendation that patients who develop unilateral testicular germ cell tumors should be followed carefully over their lifetimes. The interval between development of a first and second tumor can be 20 or more years, according to their retrospective, 50-year review.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.